Table 2.

Treatment-related adverse events occurring two or more participants and all grade 3/4 treatment-related adverse events (all cycles)

Grade 1Grade 2Grade 3Grade 4Any grade
ToxicityDose escalationThyroid expansionDose escalationThyroid expansionDose escalationThyroid expansionDose escalationThyroid expansionDose escalationThyroid expansion
Abdominal pain302021007 (27%)1 (8%)
Alopecia130000001 (4%)3 (23%)
Anorexia8333000011 (42%)6 (46%)
Arthralgia101000002 (8%)0
Blurry vision/vision changes0200000002 (15%)
Constipation311100004 (15%)2 (15%)
Cracking skin300000003 (12%)0
Diarrhea10286430022 (85%)11 (85%)
Dizziness530000005 (19%)3 (23%)
Dry eyes/mouth400000004 (15%)0
Dry skin420000004 (15%)2 (15%)
Edema531000006 (23%)3 (23%)
Decreased EF0002000002 (15%)
Epistaxis300000003 (12%)0
Esophageal ulcer0000010001 (8%)
Fatigue8662210016 (62%)9 (69%)
Flatulence300000003 (12%)0
Headache401010006 (23%)0
Heartburn201000003 (12%)0
Hypertension4273360014 (54%)11 (85%)
Hypokalemia200000002 (8%)0
Hypomagnesemia310000003 (12%)1 (8%)
Hypopigmentation230000002 (8%)3 (23%)
Mucositis440000004 (15%)4 (31%)
Muscle cramping201000003 (12%)0
Muscle weakness200010003 (12%)0
Nausea/vomiting12745000016 (62%)12 (92%)
Neutropenia100100001 (4%)1 (8%)
Palmar–plantar erythrodysesthesia110100001 (4%)2 (15%)
Proteinuria001110002 (8%)1 (8%)
Pruritus210001002 (8%)2 (15%)
Rash13545130018 (69%)13 (100%)
Taste changes542100007 (27%)5 (38%)
Thrombocytopenia211100003 (12%)2 (15%)
Transaminitis310251008 (31%)4 (31%)
Weight loss321001004 (15%)1 (8%)